NCCN 2023 Annual Congress: Hematologic Malignancies features expert perspectives on developments in blood cancer treatment, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Updates, CAR T-Cell therapy, BTK Inhibitors, Bispecific T-Cell Engagers, and More
SAN FRANCISCO, Sept. 18, 2023 /PRNewswire/ — The National Comprehensive Cancer Network® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco this week, for the first time since 2019. The meeting features insights from world-renowned experts on providing optimal, evidence-based treatment for various blood cancers, plus best practices for protecting vulnerable populations in a changing healthcare landscape.
The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square. For full details and to register, visit NCCN.org/hem.
“We designed a comprehensive program for the entire hematology and oncology team—taking into account the latest advances, conversations, and controversies in blood cancer treatment today,” said congress Chair Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center. “Attendees from all over the world can learn about the most up-to-date evidence and expert consensus for improving outcomes for patients with a variety of hematologic malignancies. The event also provides opportunities for networking and questions with leading experts in the field.”
The hybrid event is back in California for the first time in four years, following last year’s meeting in New York City. Attendees are also able to attend live online via NCCN’s easy-to-use virtual platform. Sessions will remain accessible on-demand for 60 days following the event for all registrants.
Some of this year’s featured topics include:
- Identifying and managing toxicities in patients receiving CAR T-cell therapy
- Revolutionizing hematologic cancer treatment with bispecific T-cell engagers
- Integrating new WHO/ICC classification systems
- Tackling inequities in access and quality of care for patients with multiple myeloma
- Managing graft-versus-host disease in transplant recipients
- Prevention and management of blood clots
Speakers will also share information and research pertaining to the treatment of Adult Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), B-Cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Chronic Myeloid Leukemia, Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM), Myelodysplastic Syndromes (MDS), Myelofibrosis (MF), and Waldenström Macroglobulinemia (WM).
“This conference seeks to provide clear, understandable, and actionable updates to help busy care providers analyze, evaluate, and contextualize new clinical data,” said Wui-Jin Koh, MD, Senior Vice President, Chief Medical Officer, NCCN. “This will help us all to achieve the best possible outcomes for people with blood cancer in a rapidly evolving landscape.”
Save the dates: the NCCN 2024 Annual Conference will be happening in Orlando, FL April 5 – 7, 2024. Visit NCCN.org/conference for more information.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
Media Contact:
Rachel Darwin
267-622-6624
[email protected]
SOURCE National Comprehensive Cancer Network
